Supporting Adult Patients With Anti-AChR Antibody Positive gMG in Their Treatment Journeys: A Look at a Program
Andrew Gordon, MD
PeerTreating Anti-AChR Antibody Positive gMG: Clinical Trials for 2 Treatment Options
Tuan H. Vu, MD
PeerUnderstanding the Key Role of FcRn in Anti-AChR Antibody Positive gMG
Nicholas J. Silvestri, MD, FAAN
PeerExamining 2 Treatment Options for Anti-AChR Antibody Positive gMG: An Overview of the Trial Designs
Charulatha P. Nagar, MD
PeerUnderstanding Individualized Treatment Goals for gMG
Beth Stein, MD
PeerUnderstanding the Dosing and Administration of 2 Treatment Options for Anti-AChR Antibody Positive gMG
Jennifer Buczyner, MD
PeerAn Approach to Treating BPDCN Patients with Prior or Concomitant Hematologic Malignancies
Advances in BPDCN Treatment: Targeting Its Pathophysiology
James Foran, MD
PeerManaging BPDCN as a Targeted Treatment Option
Behind the Scenes of Care: Supporting Patients with Relapsed Refractory Multiple Myeloma
Bennett H. Myers, MD
PeerBispecific Antibody Treatment in Relapsed or Refractory Multiple Myeloma
Spleen Volume Reduction & Long-Term Survival in Myelofibrosis
Ruben Mesa, MD, FACP, MPN Expert
PeerManaging Anemia in Patients With Myelofibrosis
Ruben Mesa, MD, FACP, MPN Expert
PeerDurable Hct Control in Patients with Polycythemia Vera
Andrew Kuykendall, MD, MPN Expert
Peer